AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
10 avr. 2024 08h00 HE
|
Adrenomed AG
With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27 févr. 2024 15h52 HE
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment
12 févr. 2024 08h30 HE
|
HelixBind
Study shows RaPID/BSI assay can accurately identify bloodstream infections associated with sepsis in patients undergoing antimicrobial treatment.
Pancreatic Stone Protein Testing Market revenue to reach USD 5 Billion by 2033, says Research Nester
07 févr. 2024 07h30 HE
|
Research Nester
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global pancreatic stone protein testing market size is predicted to grow at a CAGR of over ~3% from 2023 to 2033. The market is projected to garner a...
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
16 oct. 2023 14h40 HE
|
BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
08 sept. 2023 04h00 HE
|
Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
01 sept. 2023 16h43 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
31 août 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
Our Lady of the Lake Health First in Nation to Implement Life-Saving Sepsis Detection Technology
02 août 2023 10h10 HE
|
Franciscan Missionaries of Our Lady Health System
Baton Rouge, LA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A first-of-its-kind, life-saving diagnostic tool that detects sepsis in patients in under 10 minutes is now in use at Our Lady of the Lake Regional...
Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien Biotechnologies, Basilea, Vivacelle Bio, Sanofi, BioAegis, Pharmazz
29 juin 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, June 29, 2023 (GLOBE NEWSWIRE) -- Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien...